Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma

Five-year follow-up of S1106 demonstrates similar efficacy, MRD negativity, and 5-year survival with RH or RB, but RH was more toxic than RB. RB showed excellent efficacy and survival and less toxicity compared with a cytarabine-based regimen in transplant-eligible MCL patients.

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Kamdar, Manali, Li, Hongli, Chen, Robert W., Rimsza, Lisa M., Leblanc, Michael L., Fenske, Timothy S., Shea, Thomas C., Barr, Paul M., Phillips, Tycel J., Leonard, John P., Kahl, Brad S., Friedberg, Jonathan W., Smith, Sonali M.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2019
Matèries:
Stimulus Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849956/
https://ncbi.nlm.nih.gov/pubmed/31648328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000526
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars